| Status : Published | Published On : Dec, 2023 | Report Code : VRHC1235 | Industry : Healthcare | Available Format :
|
Page : 280 |
Global Digital Biomarkers Market – Analysis and Forecast (2025-2030)
Industry Insight by System Component (Data Collection Tools (Digital Platforms, Mobile Apps, Desktop-Based Software, Wearable, and Biosensors) and Data Integration Systems), by Therapeutic Area (Cardiovascular Diseases, Neurodegenerative Disorders, Sleep and Movement Diseases, Psychiatric Disorders, Chronic Pain, Gastrointestinal Diseases, Diabetes, Respiratory Diseases, and Others), by Application (Wellness, Disease Diagnosis, Personalized Medication, and Drug Discovery and Development), by Development Status (Novel Digital Biomarkers, Original Digital Biomarkers, and Approved Digital Biomarkers), by End-User (Pharmaceutical Companies & Labs, Healthcare Providers, and Insurance Payers),and Geography (U.S., Canada, Germany, U.K., France, China, Japan, India, and Rest of the World)
Industry Overview
The Global Digital Biomarkers Market is expected to grow from USD 0.86 billion to USD 5.4 billion by 2030 at a CAGR of 22.5% during the forecast period ranging from 2025 to 2030.
Digital biomarkers use digital technologies, such as sensors, wearable devices, and mobile applications, to collect and analyze physiological, behavioral, and environmental data to evaluate an individual's health condition. These devices also help in monitoring the progress of a disease by measuring and tracking different pathological and anatomical features of an individual. Especially helpful for patients suffering from chronic diseases, the biomarkers help in providing quality healthcare by doctors who can track and measure the symptoms of the patient early. These are also used extensively in clinical care and clinical trials.
The growth of the global digital biomarkers market is the result of higher penetration of smartphones and the use of health-related mobile apps, as well as the rise in acceptance and use of connected digital devices. The significant development of wearable devices also promotes market growth.
The growth of the global digital biomarkers market is somewhat hindered by the growing concerns over data privacy and security breaches. The rise in the demand for data-driven, more efficient, and customized healthcare solutions is however creating promising growth opportunities for the market.
Market Segmentation
Insight by System Component
The global digital biomarkers market is divided by system components into data collection tools and data integration systems segments, where the former is further divided into digital platforms, mobile apps, desktop-based software, wearable, and biosensors and will grow more due to the penetration of digital tools like smartphones and wearables to collect health information.
Insight by Therapeutic Area
The global digital biomarkers market is also split by therapeutic area into cardiovascular diseases, neurodegenerative disorders, sleep and movement diseases, psychiatric disorders, chronic pain, gastrointestinal diseases, diabetes, respiratory diseases, and other segments. Among all these segments, the cardiovascular diseases segment will grow more due to the provision of in-depth insights into the response of a cardiac patient during standardized activity. It also helps in improving cardiac rehab outcomes. However, the chronic pain segment is expected to grow at a faster rate during the forecast period due to the development and adoption of AR and VR solutions for finding and treating chronic pain.
Insight by Application
According to the application, the global digital biomarkers market is segmented into wellness, disease diagnosis, personalized medication, and drug discovery and development segments. Out of all these segments, the drug discovery and development segment will grow at a higher CAGR due to the growing adoption of AI cloud-based services in the pharmaceutical industry to allow cost-effective and efficient drug discovery.
Insight by Development Status
The global digital biomarkers market is also divided by development status into novel digital biomarkers, original digital biomarkers, and approved digital biomarkers segments. Out of these segments, the approved digital biomarkers segment is expected to grow more in terms of revenue during the forecast period due to higher reliability and legal authenticity being FDA-approved.
Insight by End-User
End users also divide the global digital biomarkers market into pharmaceutical companies & labs, healthcare providers, and insurance payers’ categories. Out of these segments, the pharmaceutical companies will grow more and contribute the largest share due to their contribution to the development of drugs by providing novel data for researchers to understand the progression of the disease and understand the performance or response of the patients towards the drugs. This helps pharmaceutical companies develop customized drugs according to the specifications of patients, pushing demand and growth.
Global Digital Biomarkers Market Report Coverage
|
Report Metric |
Details |
|
Historical Period |
2018 - 2023 |
|
Base Year Considered |
2024 |
|
Forecast Period |
2025 - 2030 |
|
Market Size in 2023 |
U.S.D. 0.86 Billion |
|
Revenue Forecast in 2030 |
U.S.D. 5.4 Billion |
|
Growth Rate |
22.5% |
|
Segments Covered in the Report |
By System Component, By Therapeutic Area, By Application, By Development Status and By End-User |
|
Report Scope |
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling |
|
Regions Covered in the Report |
North America, Europe, Asia-Pacific, Middle East, South America and Rest of the World |
Industry Dynamics
Industry Trends
There is a growing acceptance of 3G, 4G, and other high-speed networks, and significant developments noticed in information technology apart from facilitating the use of these solutions. In addition, the growing demand for these systems is also reducing the cost of healthcare significantly. These solutions are also used extensively to treat persistently ill patients. In addition, there is a surge in the use of wearable devices, such as smartwatches and fitness trackers, for disease management and health monitoring.
Growth Drivers
The existence of a large number of major industry players and their continual effort to develop their products and make new launches fuel the market growth significantly. Supportive government initiatives, speedy FDA approval, the need for alternatives due to the failure of drugs for neurodegenerative disorders, growing mental and other health issues, diabetes, cardiovascular diseases, and BP are some other factors that push the market forward.
Challenges
Typically, the strict government regulations coupled with the stringent standardization procedures hinder the growth of the digital biomarkers market. Furthermore, the lack of proper training to handle the systems and the absence of strategic planning and coordination hinders the market growth.
Opportunities
The potential to improve healthcare outcomes by facilitating early disease detection, the advent of tailored medicine, and higher investment in wearable technology and voice-based digital biomarkers offer novel growth opportunities to the global digital biomarkers market.
Geographic Overview
North America will lead the market with its largest share during the forecast period due to the existence of a large number of prominent industry players launching newer and better products, higher investment in R&D, and rising approval of smart devices.
Asia Pacific is expected to grow at a faster rate due to the growing importance of government in improving healthcare infrastructure, the growing adoption of smart devices, and the rise in the number of chronic disease incidents in the region.
Competitive Insight
The industry Players are focusing on R&D in product development and want to build their brand value. Various other strategies such as mergers and acquisitions, collaborating with research and medical institutions, and expanding their presence in the digital biomarkers market.
AliveCor Labs' digital tools help patients access, manage and share their data, and connect with cardiologists to better understand and manage their heart health.
Digital and video resources are available on biomarker testing for solid tumors and hematology, as well as a comprehensive precision medicine digital binder in Novartis AG.
Some of the key players operating in the global digital biomarkers market are AliveCor Labs, Eli Lilly and Company, Biogen, Novartis AG, Fitbit LLC, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Pfizer Inc., and Takeda Pharmaceutical Company Limited.
Recent Developments by Key Players
Novartis has received approval from the US Food and Drug Administration (FDA) for commercial manufacturing of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) at its new large-scale, state-of-the-art radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States.
Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson's disease. As part of the agreement, Biogen will licence Konectom to Indivi, a smartphone-based digital biomarker platform that assesses neurological functions remotely for more precise, frequent measurement of disease evolution.
The Digital Biomarkers Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2025–2030.
Segments Covered in the Report
- By System Component
- Data Collection Tools
- Digital Platforms
- Mobile Apps
- Desktop-Based Software
- Wearable
- Biosensors
- Data Integration Systems
- Data Collection Tools
- By Therapeutic Area
- Cardiovascular Diseases
- Neurodegenerative Disorders
- Sleep and Movement Diseases
- Psychiatric Disorders
- Chronic Pain
- Gastrointestinal Diseases
- Diabetes
- Respiratory Diseases
- Others
- By Application
- Wellness
- Disease Diagnosis
- Personalized Medication
- Drug Discovery and Development
- By Development Status
- Novel Digital Biomarkers
- Original Digital Biomarkers
- Approved Digital Biomarkers
- By End-User
- Pharmaceutical Companies & Labs
- Healthcare Providers
- Insurance Payers
Region Covered in the Report
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia-Pacific (APAC)
- China
- Japan
- India
- South Korea
- Rest of Asia-Pacific
- Rest of the World (RoW)
- Brazil
- Saudi Arabia
- South Africa
- U.A.E.
- Other Countries
.png "Digital Biomarkers Market Size")
Source: VynZ Research
Source: VynZ Research
Frequently Asked Questions
Place an order
Latest Report
Research Methodology
- Desk Research / Pilot Interviews
- Build Market Size Model
- Research and Analysis
- Final Deliverabvle
CONNECT WITH OUR SALES TEAM
- Toll-Free: 1 888 253 3960
- Phone: +91 9960 288 381
- Email: enquiry@vynzresearch.com
Digital Biomarkers Market